Unraveling the Complexities of Cardiometabolic Diseases: Interdisciplinary Insights and Innovative Approaches

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Epidemiology, Lifestyle, and Cardiovascular Health".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 769

Special Issue Editor


E-Mail
Guest Editor
1. Department of Internal Medicine, University Hospital of Ioannina, 45110 Ioannina, Greece
2. Department of Hygiene and Epidemiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece
Interests: dyslipidemia; hypercholesterolemia; obesity; diabetes; cardiovascular disease; atherosclerosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiometabolic diseases represent a complex constellation of conditions that intertwine cardiovascular health with metabolic dysfunction. This broad spectrum of disorders encompasses dyslipidemia, obesity, hypertension, elevated glucose levels or diabetes and chronic kidney disease, and cardiovascular disease. Together, they pose a formidable challenge to public health worldwide, contributing significantly to morbidity, mortality, and healthcare expenditures.

Despite advances in preventive and therapeutic strategies, cardiometabolic diseases continue to exact a heavy toll on individuals and healthcare systems globally. The multifactorial nature of these conditions necessitates a holistic approach to prevention, early detection, and management. Addressing one aspect in isolation is insufficient; instead, comprehensive strategies are required to tackle the underlying metabolic dysregulation and mitigate the cascade of cardiovascular complications.

In this Special Issue, we aim to delve into the intricate web of cardiometabolic diseases, examining the synergistic relationships between dyslipidemia, obesity, hypertension, chronic kidney disease, and cardiovascular disease. By fostering interdisciplinary collaboration and sharing the latest research findings ranging from basic to translational and clinical science, we will strive to elucidate novel insights and innovative approaches for the prevention, diagnosis, and treatment of these interconnected disorders.

We invite researchers, clinicians, and experts in the field to contribute their original research articles and comprehensive reviews to this Special Issue. Together, let us endeavor to confront the challenges of cardiometabolic diseases head-on and advance the collective efforts towards a healthier future for all.

Dr. Fotios Barkas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular disease
  • dyslipidemia
  • obesity
  • diabetes
  • hypertension
  • renal disease

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 674 KiB  
Review
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
by Francesco Natale, Ettore Luisi, Rosa Franzese, Noemi Mollo, Achille Solimene, Valentina Maria Caso, Andrea Corvino, Paolo Golino and Giovanni Cimmino
J. Cardiovasc. Dev. Dis. 2024, 11(5), 145; https://doi.org/10.3390/jcdd11050145 - 7 May 2024
Viewed by 631
Abstract
Cardiovascular diseases remain the main cause of death and disability worldwide. Despite the tremendous improvement in pharmacological, minimally invasive and rehabilitative strategies, global deaths due to cardiovascular diseases are still increasing. Additional risk factors have been recently proposed, and thanks to scientific progress, [...] Read more.
Cardiovascular diseases remain the main cause of death and disability worldwide. Despite the tremendous improvement in pharmacological, minimally invasive and rehabilitative strategies, global deaths due to cardiovascular diseases are still increasing. Additional risk factors have been recently proposed, and thanks to scientific progress, novel drugs for the control of the main risk factors focusing on the cardiometabolic pathways have been identified. Glucagon-like peptide-1 (GLP-1) receptor agonists represent an innovative step in the management of patients affected by type 2 diabetes mellitus. In addition to their significant efficacy on glycemic homeostasis, some members of this class of drugs have indications in the treatment of obesity. Furthermore, accumulated evidence in the literature has finally suggested a protective role in cardiovascular health. The possible role of GLP-1R agonist drugs (GLP-1RAs) on the mechanisms underlying chronic inflammation and the almost ubiquitous distribution of GLP-1 receptors could explain the enormous versatility of these drugs. Semaglutide is a GLP-1RA recently proven to be effective in cardiovascular outcomes. In the present article, we will review the available data on semaglutide in light of the most recent publications to better characterize the target population achieving cardiovascular benefits. Full article
Show Figures

Figure 1

Back to TopTop